Reyon Pharmaceutical Co Ltd (102460) — Cash Flow Quality Index
Reyon Pharmaceutical Co Ltd (102460) has a Cash Flow Quality Index of 11.17x as of March 2025. Operating cash flow of ₩2.41 Billion exceeds net income of ₩216.09 Million, indicating high earnings quality where cash backs reported profits. Explore cash efficiency ratio of Reyon Pharmaceutical Co Ltd to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Reyon Pharmaceutical Co Ltd Cash Flow Quality Index (2008–2024)
Historical Cash Flow Quality Index for Reyon Pharmaceutical Co Ltd across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 102460 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Reyon Pharmaceutical Co Ltd (2008–2024)
Year-by-year earnings quality comparison for Reyon Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see Reyon Pharmaceutical Co Ltd market capitalisation.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.35x | ₩-1.44 Billion | ₩4.15 Billion | ▼ -114.3% |
| 2023 | 2.41x | ₩8.65 Billion | ₩3.58 Billion | ▲ +105.5% |
| 2022 | 1.17x | ₩8.73 Billion | ₩7.43 Billion | ▼ -44.4% |
| 2021 | 2.11x | ₩11.68 Billion | ₩5.54 Billion | ▲ +76.4% |
| 2020 | 1.20x | ₩4.60 Billion | ₩3.84 Billion | ▲ +158.3% |
| 2019 | -2.05x | ₩-12.18 Billion | ₩5.94 Billion | ▼ -124.1% |
| 2018 | 8.53x | ₩11.45 Billion | ₩1.34 Billion | ▲ +555.4% |
| 2017 | 1.30x | ₩16.76 Billion | ₩12.89 Billion | ▲ +47.0% |
| 2016 | 0.89x | ₩9.47 Billion | ₩10.70 Billion | ▼ -39.0% |
| 2012 | 1.45x | ₩24.65 Billion | ₩16.99 Billion | ▲ +87.0% |
| 2011 | 0.78x | ₩15.34 Billion | ₩19.78 Billion | ▲ +45.5% |
| 2009 | 0.53x | ₩8.68 Billion | ₩16.29 Billion | ▼ -30.2% |
| 2008 | 0.76x | ₩5.99 Billion | ₩7.84 Billion | — |